GSGabriel Yuri Storino

Gabriel Yuri Storino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriel Yuri Storino has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Health–Economic Impact Attributable to Occurrence of Pleurisy and Pneumonia Lesions in Finishing Pigs

    by Clarisse S. Malcher, Fernando A. M. Petri, Laiza P. Arruda, Gabriel A. de Aguiar, Gabriel Y. Storino, Karina Sonalio, Leonardo T. Toledo, Flávio Hirose, Luís Guilherme de Oliveira

    Respiratory diseases, such as pleurisy and pneumonia, cause significant health and economic losses in pig production. This study evaluated 867 finishing pigs from a farm with a history of respiratory issues, using macroscopic lesion scoring (SPES and CVPC), histopathological analysis, qPCR diagnostics, and economic modeling. Severe pleurisy (scores 3 and 4) was observed in 42.1% of carcasses and was strongly correlated with higher bacterial loads of Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, and Pasteurella multocida. Severe lesions reduced the average daily gain (ADG) and carcass weight, leading to increased production costs and lower profitability. Economic analysis revealed that pigs with higher pleurisy scores incurred an additional cost per kg (USD 1.29 vs. USD 1.32 for milder cases), reduced total revenue by 1.36%, and decreased return on investment (ROI) from 5.33% to 3.90%. These findings emphasize the critical impact of respiratory diseases on profitability and the necessity of robust health management strategies, including vaccination and enhanced biosecurity, to minimize economic losses in swine farming.


  • Open Access

    Associations between Pleurisy and the Main Bacterial Pathogens of the Porcine Respiratory Diseases Complex (PRDC)

    by Fernando Antônio Moreira Petri, Geovana Coelho Ferreira, Laíza Pinto Arruda, Clarisse Sena Malcher, Gabriel Yuri Storino, Henrique Meiroz de Souza Almeida, Karina Sonalio, Daniela Gomes da Silva, Luís Guilherme de Oliveira

    Porcine Respiratory Diseases Complex (PRDC) is a multifactorial disease that involves several bacterial pathogens, including Mycoplasma hyopneumoniae (M. hyopneumoniae), Actinobacillus pleuropneumoniae (A. pleuropneumoniae), Pasteurella multocida (P. multocida), Glaesserella parasuis (G. parasuis), and Streptococcus suis (S. suis). In pigs, the infection may cause lesions such pleurisy, which can lead to carcass condemnation. Hence, 1015 carcasses were selected from three different commercial pig farms, where the respiratory conditions were evaluated using slaughterhouse pleurisy evaluation system (SPES) and classified into five groups. In total, 106 pleural and lung fragments were collected for qPCR testing to identify the five abovementioned pathogens. A moderate correlation between the severity of the lesions and the presence of P. multocida (R = 0.38) and A. pleuropneumoniae (R = 0.28) was observed. Concerning the lung samples, the severity of the lesions was moderately correlated with the presence of P. multocida (R = 0.43) and M. hyopneumoniae (R = 0.35). Moreover, there was a strong correlation between the presence of P. multocida and M.hyopneumoniae in the pleura (R = 0.82). Finally, this approach may be a useful tool to identify and quantify causative agents of PRDC using qPCR, providing a comprehensive evaluation of its relevance, strength, and potential application in the field as a surveillance tool for veterinarians.


  • Open Access

    Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control Mycoplasma hyopneumoniae in Swine Production

    by Gabriel Y. Storino, Fernando A. M. Petri, Marina L. Mechler-Dreibi, Gabriel A. Aguiar, Leonardo T. Toledo, Laíza P. Arruda, Clarisse S. Malcher, Tereza S. Martins, Hélio J. Montassier, Osvaldo A. Sant’anna, et al.

    Mycoplasma hyopneumoniae is a difficult-to-control bacterium since commercial vaccines do not prevent colonization and excretion. The present study aimed to evaluate the performance of an orally administered vaccine composed of antigens extracted from Mycoplasma hyopneumoniae and incorporated into mesoporous silica (SBA-15), which has an adjuvant-carrier function, aiming to potentiate the action of the commercial intramuscular vaccine. A total of 60 piglets were divided into four groups (n = 15) submitted to different vaccination protocols as follows, Group 1: oral SBA15 + commercial vaccine at 24 days after weaning, G2: oral vaccine on the third day of life + vaccine commercial vaccine at 24 days, G3: commercial vaccine at 24 days, and G4: commercial vaccine + oral vaccine at 24 days. On the first day, the piglets were weighed and, from the third day onwards, submitted to blood collections for the detection and quantification of anti-Mycoplasma hyopneumoniae IgG. Nasal swabs were collected to monitor IgA by ELISA, and oropharyngeal swabs were used to assess the bacterial load by qPCR. Biological samples were collected periodically from the third day of life until the 73rd day. At 41 days of life, 15 individuals of the same age, experimentally challenged with an inoculum containing M. hyopneumoniae, were co-housed with the animals from groups (1 to 4) in a single pen to increase the infection pressure during the nursery period. At 73 days, all piglets were euthanized, and lungs were evaluated by collecting samples for estimation of bacterial load by qPCR. Quantitative data obtained from physical parameters and laboratory investigation were analyzed by performing parametric or non-parametric statistical tests. Results indicate that animals from G2 showed smaller affected lung areas compared to G3. Animals from G2 and G4 had a low prevalence of animals shedding M. hyopneumoniae at 61 days of age. Additionally, no correlation was observed between lung lesions and M. hyopneumoniae load in lung and BALF samples in animals that received the oral vaccine, while a strong correlation was observed in other groups. In the present study, evidence points to the effectiveness of the oral vaccine developed for controlling M. hyopneumoniae in pig production under field conditions.


  • Efficacy evaluation of a novel oral silica-based vaccine in inducing mucosal immunity against Mycoplasma hyopneumoniae

    by Geovana C. Ferreira, Thainara V.C. Sanches, Marina L. Mechler-Dreibi, Henrique M.S. Almeida, Gabriel Y. Storino, Karina Sonalio, Fernando A.M. Petri, Tereza S. Martins, Luís Carlos Cides da Silva, Hélio J. Montassier, et al.


  • Open Access

    Chemotherapeutic Strategies with Valnemulin, Tilmicosin, and Tulathromycin to Control Mycoplasma hyopneumoniae Infection in Pigs

    by Giovani Marco Stingelin, Marina Lopes Mechler-Dreibi, Gabriel Yuri Storino, Karina Sonalio, Henrique Meiroz de Souza Almeida, Fernando Antônio Moreira Petri, Luís Guilherme de Oliveira

    Mycoplasma hyopneumoniae is the primary agent of Swine Enzootic Pneumonia (SEP). Vaccines reduce the clinical manifestation of the disease but do not prevent infection. The present study aimed to evaluate the use of antimicrobial drugs to minimize the impact of M. hyopneumoniae. For this, 32 pregnant female pigs and their litters were selected and then followed from birth to slaughter. The study involved three experimental groups that received metaphylactic treatment with different protocols involving tilmicosin, valnemulin, tulathromycin, and a control group to compare the effect of treatments against M. hyopneumoniae infection throughout the phases. Performance data were recorded, and the piglets were evaluated for the occurrence of cough. Nasal swab and blood collection was conducted periodically to detect M. hyopneumoniae shedding and anti-M. hyopneumoniae IgG, respectively. At slaughter, the lungs of animals from all groups were evaluated, and samples were collected for histopathological examination and qPCR for M. hyopneumoniae detection. All protocols promoted a reduction in consolidation lung lesions when compared to the control group. Individuals treated with valnemulin showed increased performance results, lower mortality, and low bacterial load in the lung. The results are promising and may indicate an alternative in the strategic control of M. hyopneumoniae infection in pigs.